Treatment with midostaurin and other FLT3 targeting inhibitors is associated with an increased risk of cardiovascular adverse events in patients who underwent allogeneic hematopoietic stem cell transplantation with FLT3-mutated AML

The addition of midostaurin to standard chemotherapy has improved survival in patients with FLT3-mutated AML. However, the impact of midostaurin and other FLT3 inhibitors (FLT3i) on cardiovascular adverse events (CAEs) has not been studied in patients who underwent allogeneic hematopoietic stem cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Cremer, Anjali, Enssle, Julius C., Pfaff, Saskia, Kouidri, Khouloud, Lang, Fabian, Brandts, Christian, Zeiher, Andreas, Cremer, Sebastian, Steffen, Björn, Serve, Hubert, Bug, Gesine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492676/
https://www.ncbi.nlm.nih.gov/pubmed/37552323
http://dx.doi.org/10.1007/s00277-023-05396-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492676/
https://www.ncbi.nlm.nih.gov/pubmed/37552323
http://dx.doi.org/10.1007/s00277-023-05396-y

Ejemplares similares